对DNA结合,酶抑制和细胞毒性活动进行探索的新合成的硫胺衍生物:混合计算和实验分析
Nasima Arshad1, Yasir Mehmood1, Hammad Ismail2
1Department of Chemistry, Allama Iqbal Open University 44000 Islamabad Pakistan nasimaa2006@yahoo.com nasima.arshad@aiou.edu.pk.
RSC advances
|November 5, 2024
概括
合成了三种新的硫胺衍生物,并对它们的生物活性进行了评估. 衍生品YM-1显示出有前途的DNA结合和碳酸无水酶抑制,而YM-2则是一种强大的尿酶抑制剂,并且都表现出抗癌性质.
科学领域:
- 药用化学 医学化学
- 异环化学 异环化学
- 生物化学 生物化学
背景情况:
- 硫胺衍生物由于其多样化的生物活性,在药物发现中至关重要.
- 融合异环系统为开发新型治疗剂提供了独特的支架.
- 了解药物向相互作用是设计有效治疗的关键.
研究的目的:
- 为了合成和表征基于 thiazolo[3,4-d]isoxazole 的新型硫胺衍生物.
- 研究这些化合物的DNA结合相互作用和酶抑制潜力.
- 为了评估癌症和健康细胞系的体外细胞毒性.
主要方法:
- 三种硫胺衍生物 (YM-1,YM-2,YM-3) 的合成和表征.
- 实验方法:紫外线可见,光,循环电压测量,用于DNA结合的粘度测量.
- 酶抑制试验 (尿酶,碳酸) 和MTT细胞毒性试验.
- 理论方法:用于DNA和酶相互作用的分子对接.
主要成果:
- 所有的衍生物通过混合的介质和沟结合机制显示出显著的DNA结合亲和力,YM-1显示出最高亲和力.
- YM-1 呈现出优异的碳酸无水酶抑制,而 YM-2 显示出强大的尿酶抑制.
- 衍生品对MG-U87癌细胞表现出剂量依赖的细胞毒性 (70-90%的抑制).
- 与阳性对照组相比,YM-1对健康的HEK-293细胞的毒性较低.
结论:
- 硫胺衍生物YM-1是DNA结合和抗癌疗法的有希望的候选者.
- YM-2 显示出作为抗尿剂的潜力.
- 合成的化合物代表了用于进一步药物开发的有价值的分子类.
更多相关视频
06:07Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
2.5K
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
427
相关概念视频
Structure-Activity Relationships and Drug Design
611
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
611
Single-Strand DNA Binding Proteins
13.9K
For successful DNA replication, the unwinding of double-stranded DNA must be accompanied by stabilization and protection of the separated single strands of the DNA. This crucial task is performed by single-strand DNA-binding (SSB) proteins. They bind to the DNA in a sequence-independent manner, which means that the nitrogenous bases of the DNA need not be present in a specific order for binding of SSB proteins to it. The binding of SSB proteins straightens single-stranded DNA (ssDNA) and makes...
13.9K
Restriction Enzymes
29.6K
Restriction enzymes are bacterial enzymes used to cut DNA in a sequence-specific manner. To cleave DNA, they bind to specific palindromic sequences called restriction sites. Such palindromic DNA sequences or inverted repeats are commonly found in regions of functional significance, such as the origin of replication, gene operator sites, and regions containing transcription termination signals.
The host bacteria protect their own genomic DNA from these enzymes by methylating these sites. Some...
The host bacteria protect their own genomic DNA from these enzymes by methylating these sites. Some...
29.6K
Targets for Drug Action: Overview
6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K
